{"url_path":"/sec/fenc/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1211583/0001104659-26-061213-index.html","accession_number":"0001104659-26-061213","cik":"0001211583","ticker":"FENC","issuer_name":"FENNEC PHARMACEUTICALS INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1211583/0001104659-26-061213-index.html","primary_entity_key":"0001211583","primary_entity_name":"FENNEC PHARMACEUTICALS INC."},"word_count":145,"has_tables":true,"body_markdown":"**Item 5. Other Information**\n\n*Insider Trading Arrangements and Policies*\n\nDuring the quarter ended March 31, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulations S-K.\n\n​\n\n*Press Release*\n\nOn May 14, 2026, we issued a press release announcing our financial results for the quarter ended March 31, 2026. A copy of the news release is attached to this Quarterly Report as Exhibit 99.1. The press release is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or\n\n30\n\n[Table of Contents](#TOC)\n\nincorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references the press release."}